Erbitux Sales Data
Last updated: May 2013 (updated quarterly).
The following data shows Erbitux U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q2 2012 | 95 ( 4) |
$167,914 | -2.10% | 262 | -1.50% |
| Q1 2012 | 99 ( 2) |
$171,513 | 2.30% | 266 | 3.91% |
| Q4 2011 | 97 (7) |
$167,657 | -0.15% | 256 | 0.79% |
| Q3 2011 | 90 (3) |
$167,909 | -2.48% | 254 | -1.93% |
| Q2 2011 | 93 (2) |
$172,185 | -0.89% | 259 | -0.38% |
| Q1 2011 | 95 | $173,735 |  |
260 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| July 9, 2012 | FDA Oks Screening Test for Colon Cancer Drug |
| November 7, 2011 | Erbitux Approval Expanded to Include Head and Neck Cancer |
| June 9, 2011 | Chemo for Late-Stage Cancer Patients May Be Unjustified |
| December 20, 2010 | Rash Due to Lung Cancer Drug May Be Linked to Better Survival |
| October 26, 2010 | New Insights on Who Should Take Erbitux for Colon Cancer |
| October 11, 2010 | Erbitux Drug Fails In Colon Cancer Study That May Limit Its Use |
| April 1, 2009 | Erbitux May Help Some With Colorectal Cancer |
| October 22, 2008 | Colon Cancer Drug Won't Help Those With Certain Gene Mutation |
